Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios

Cemiplimab, a monoclonal antibody directed against programmed death receptor 1 (PD-1), has shown promising results in cutaneous squamous cell carcinoma (cSCC). In a nonrandomized trial where cemiplimab 3 mg/kg was given every 2 weeks for up to 96 weeks, a 44% response rate was noted. This case serie...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Komal Akhtar MD (लेखक), Metlapalli Venkata Sravanthi MD (लेखक), Josephine D'Angelo MD (लेखक), Abirami Sivapiragasam MD (लेखक)
स्वरूप: पुस्तक
प्रकाशित: SAGE Publishing, 2022-08-01T00:00:00Z.
विषय:
ऑनलाइन पहुंच:Connect to this object online.
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

इंटरनेट

Connect to this object online.

3rd Floor Main Library

होल्डिंग्स विवरण से 3rd Floor Main Library
बोधानक: A1234.567
प्रति 1 उपलब्ध